News

12 February / 2021

Binnopharm Group to Modernize the Antibiotic Production at the Kurgan Factory

The Binnopharm Group pharmaceutical holding, that unites AFK Sistema portfolio companies: Alium, JSC (includes Binnopharm, JSC) and OJSC Sintez (includes Biocom, CJSC), plans to modernize the antibiotic production at the Sintez plant in Kurgan. The plans for upgrading the production facilities have been submitted to Denis Manturov, the Minister of Industry and Trade of the Russian Federation during his visit to the Binnopharm Group’s site in Kurgan.

‘Over the past year, pharmaceutical factories stood at the forefront of the fight against COVID-19, providing our healthcare system with the necessary volume of medicines for prevention and treatment of coronavirus infection. Many factories have switched to round-the-clock operation, increasing the production of required medicines by dozens of times, and the Binnopharm Group factories were among them. Until now, these enterprises operate in an alert mode, working in several shifts. Therefore, we welcome their initiatives to modernize and update production facilities, especially for socially significant drugs.’, Denis Manturov, Minister of Industry and Trade of the Russian Federation noted.

In 2020, the Binnopharm Group Kurgan factory increased the production of antibiotics and other drugs recommended for treatment of COVID-19 by 44% due to, among other things, launching a new site for production of substances for antibiotics (project investment exceeded RUB 320 million). Moreover, last April, Sintez received a soft loan from the Industrial Development Fund of the Russian Federation in the amount of RUB 500 million to create raw material stocks and to increase the production of medicines for treatment of viral infections.

‘Last year, to ensure national security, the Binnopharm Group factories increased their production capacity and manufactured almost 100 million packages of medicines for COVID-19 prevention and treatment, the bulk having been produced at the Kurgan Sintez. We closely cooperated with the Industrial Development Fund, which supported our project to create raw material stocks and to increase the production of medicines for viral infections treatment. In the current year, we envisage to continue large-scale modernization of the factory with a particular focus on improving and expanding the antibiotic production’, Rustem Muratov, Director General of the Binnopharm Group holding said.

Sintez, the Binnopharm Group Kurgan factory, produces 300 medicines, 84 of which are included in the list of vital and essential medicines, and 14 medicines, in the recommendations of the Ministry of Health of the Russian Federation for COVID-19 treatment.